Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 58 | 11.180 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 121 | 9.940 |
Why?
|
| Portal Vein | 30 | 2022 | 42 | 8.900 |
Why?
|
| Liver | 21 | 2022 | 184 | 6.850 |
Why?
|
| Liver Regeneration | 17 | 2022 | 23 | 5.140 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 90 | 3.700 |
Why?
|
| Ligation | 22 | 2022 | 33 | 2.580 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 41 | 2.360 |
Why?
|
| Laparoscopy | 6 | 2021 | 171 | 1.730 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 9 | 1.340 |
Why?
|
| Postoperative Complications | 13 | 2022 | 996 | 1.290 |
Why?
|
| Liver Diseases | 2 | 2018 | 41 | 1.150 |
Why?
|
| Cause of Death | 3 | 2017 | 70 | 1.100 |
Why?
|
| Registries | 9 | 2019 | 203 | 1.070 |
Why?
|
| Liver Failure | 4 | 2019 | 11 | 0.970 |
Why?
|
| Humans | 56 | 2024 | 31059 | 0.940 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 33 | 0.930 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3808 | 0.860 |
Why?
|
| Hypertrophy | 5 | 2022 | 20 | 0.830 |
Why?
|
| Hypoxia | 2 | 2020 | 63 | 0.820 |
Why?
|
| Organ Size | 9 | 2019 | 108 | 0.780 |
Why?
|
| Sarcopenia | 1 | 2021 | 33 | 0.750 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3664 | 0.720 |
Why?
|
| Male | 36 | 2021 | 16488 | 0.710 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 81 | 0.690 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 64 | 0.680 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 23 | 0.680 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 128 | 0.670 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.660 |
Why?
|
| Hepatomegaly | 1 | 2018 | 6 | 0.640 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 8 | 0.640 |
Why?
|
| Publication Bias | 1 | 2018 | 8 | 0.630 |
Why?
|
| Middle Aged | 26 | 2019 | 10235 | 0.620 |
Why?
|
| Antioxidants | 1 | 2018 | 65 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 344 | 0.610 |
Why?
|
| Bibliometrics | 1 | 2018 | 28 | 0.610 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 132 | 0.610 |
Why?
|
| Oxidative Stress | 1 | 2018 | 134 | 0.610 |
Why?
|
| Female | 31 | 2021 | 17005 | 0.590 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 23 | 0.590 |
Why?
|
| Length of Stay | 5 | 2021 | 339 | 0.550 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 7 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 155 | 0.530 |
Why?
|
| Aged | 20 | 2019 | 10077 | 0.510 |
Why?
|
| Graft Rejection | 4 | 2008 | 75 | 0.470 |
Why?
|
| Animals | 8 | 2021 | 4713 | 0.460 |
Why?
|
| Liver Transplantation | 3 | 2015 | 80 | 0.450 |
Why?
|
| Catheter Ablation | 1 | 2015 | 107 | 0.440 |
Why?
|
| Hepatic Veins | 4 | 2022 | 10 | 0.430 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 67 | 0.420 |
Why?
|
| Prognosis | 8 | 2020 | 924 | 0.420 |
Why?
|
| Time Factors | 9 | 2019 | 1679 | 0.410 |
Why?
|
| Risk Factors | 10 | 2019 | 2587 | 0.410 |
Why?
|
| Feasibility Studies | 4 | 2016 | 244 | 0.390 |
Why?
|
| Operative Time | 4 | 2019 | 85 | 0.360 |
Why?
|
| Survival Rate | 6 | 2018 | 407 | 0.360 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1936 | 0.350 |
Why?
|
| Models, Animal | 3 | 2020 | 129 | 0.340 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 404 | 0.340 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 206 | 0.340 |
Why?
|
| Tissue Donors | 2 | 2021 | 81 | 0.340 |
Why?
|
| Random Allocation | 3 | 2018 | 147 | 0.330 |
Why?
|
| Isoantibodies | 2 | 2006 | 11 | 0.330 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 5 | 0.320 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 32 | 0.310 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 11 | 0.310 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 17 | 0.300 |
Why?
|
| Swine | 2 | 2018 | 92 | 0.300 |
Why?
|
| Death | 1 | 2008 | 53 | 0.300 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 28 | 0.300 |
Why?
|
| Adult | 15 | 2019 | 8945 | 0.290 |
Why?
|
| Rats, Wistar | 2 | 2017 | 45 | 0.280 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 139 | 0.280 |
Why?
|
| Patient Selection | 4 | 2018 | 246 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 271 | 0.280 |
Why?
|
| Switzerland | 3 | 2021 | 9 | 0.270 |
Why?
|
| Rats | 2 | 2020 | 870 | 0.270 |
Why?
|
| Plasmapheresis | 1 | 2006 | 14 | 0.260 |
Why?
|
| HLA Antigens | 1 | 2006 | 18 | 0.260 |
Why?
|
| Antibody Formation | 1 | 2006 | 38 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2019 | 715 | 0.260 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 1 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 6 | 0.230 |
Why?
|
| Spirituality | 1 | 2004 | 68 | 0.230 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 35 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 344 | 0.200 |
Why?
|
| Ultrasonography | 3 | 2021 | 271 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2020 | 204 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 14 | 0.200 |
Why?
|
| Databases, Factual | 3 | 2019 | 353 | 0.200 |
Why?
|
| Organ Transplantation | 1 | 2021 | 39 | 0.190 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1134 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 25 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 59 | 0.190 |
Why?
|
| Biomarkers | 3 | 2020 | 734 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 111 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 259 | 0.180 |
Why?
|
| Hospitals | 1 | 2021 | 165 | 0.180 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 3 | 0.180 |
Why?
|
| Adrenalectomy | 1 | 2019 | 2 | 0.170 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 6 | 0.170 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 7 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 85 | 0.170 |
Why?
|
| Brazil | 2 | 2016 | 46 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 99 | 0.170 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 1 | 0.170 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 3 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2015 | 150 | 0.170 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 12 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2019 | 76 | 0.160 |
Why?
|
| Liver Function Tests | 4 | 2017 | 26 | 0.160 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 2 | 0.160 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 16 | 0.160 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 14 | 0.160 |
Why?
|
| Paracrine Communication | 1 | 2018 | 6 | 0.160 |
Why?
|
| Cytoprotection | 1 | 2018 | 9 | 0.160 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 31 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 30 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2018 | 10 | 0.160 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 23 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 43 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 35 | 0.160 |
Why?
|
| Anesthesia | 1 | 2018 | 36 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 40 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 45 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 64 | 0.150 |
Why?
|
| Models, Biological | 1 | 2020 | 346 | 0.150 |
Why?
|
| Logistic Models | 3 | 2016 | 410 | 0.150 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 270 | 0.150 |
Why?
|
| Liver Circulation | 1 | 2017 | 2 | 0.150 |
Why?
|
| Portal Pressure | 1 | 2017 | 2 | 0.150 |
Why?
|
| Gastric Bypass | 1 | 2018 | 66 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 818 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2017 | 322 | 0.150 |
Why?
|
| Apoptosis | 1 | 2018 | 260 | 0.140 |
Why?
|
| Hyperplasia | 1 | 2017 | 16 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2017 | 31 | 0.140 |
Why?
|
| Melanoma | 1 | 2017 | 54 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 360 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 820 | 0.140 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 7 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2018 | 498 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 192 | 0.130 |
Why?
|
| Obesity | 1 | 2018 | 306 | 0.130 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 4 | 0.130 |
Why?
|
| Methyl Ethers | 1 | 2015 | 6 | 0.130 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 13 | 0.130 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 11 | 0.130 |
Why?
|
| Propofol | 1 | 2015 | 16 | 0.130 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 41 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 782 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2017 | 2041 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 50 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 135 | 0.120 |
Why?
|
| Surgeons | 1 | 2016 | 87 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 87 | 0.120 |
Why?
|
| Viscera | 1 | 2013 | 1 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2013 | 14 | 0.110 |
Why?
|
| Renal Artery | 1 | 2013 | 6 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 12 | 0.110 |
Why?
|
| Aneurysm | 1 | 2013 | 12 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 31 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 37 | 0.110 |
Why?
|
| Stents | 1 | 2013 | 86 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2012 | 65 | 0.100 |
Why?
|
| Bilirubin | 2 | 2016 | 7 | 0.100 |
Why?
|
| Resource Allocation | 1 | 2011 | 5 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 272 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2011 | 7 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 12 | 0.100 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 64 | 0.090 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 3 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 10 | 0.090 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 2 | 0.080 |
Why?
|
| Alemtuzumab | 1 | 2008 | 5 | 0.080 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 10 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 208 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 2 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 61 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2007 | 18 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 50 | 0.080 |
Why?
|
| Graft Survival | 1 | 2008 | 98 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 160 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2007 | 38 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 783 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 115 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 83 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 178 | 0.070 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.070 |
Why?
|
| Complement C4b | 1 | 2006 | 2 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 5196 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2018 | 453 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2006 | 98 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 22 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1897 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 8 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2024 | 30 | 0.060 |
Why?
|
| Hospitals, University | 2 | 2018 | 41 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1321 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2022 | 30 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 112 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2021 | 4 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 7 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2021 | 46 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 23 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1681 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 37 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 60 | 0.050 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.050 |
Why?
|
| Contrast Media | 1 | 2021 | 136 | 0.040 |
Why?
|
| Mitotane | 1 | 2019 | 1 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 181 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 144 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 16 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 6 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 25 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 18 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 6 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 14 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 80 | 0.040 |
Why?
|
| United States | 2 | 2018 | 2376 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 386 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 113 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 110 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 55 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 26 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2017 | 40 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 303 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 337 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 61 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 168 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1210 | 0.040 |
Why?
|
| Edema | 1 | 2017 | 40 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 105 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 14 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 7 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 6 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 286 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 230 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 430 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 872 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 68 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 3 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 85 | 0.030 |
Why?
|
| Sarcoma | 1 | 2017 | 149 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 367 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 293 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 555 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 375 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 24 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 661 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 690 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2011 | 15 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 78 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 71 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 15 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 47 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 416 | 0.020 |
Why?
|
| Child | 1 | 2012 | 1428 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 28 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 296 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 6 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2006 | 10 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 103 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 57 | 0.020 |
Why?
|